TAVANIC (levofloxacin), fluoroquinolone

Insufficient actual benefit in the treatment of complicated skin and soft tissue infections

• TAVANIC has Marketing Authorisation in the treatment of complicated skin and soft tissue infections
•  In this indication, it has no role in the therapeutic strategy given:
•  - the insufficient demonstration of efficacy in severe infections and/or infections caused by multidrug-resistant bacteria,

- its spectrum of activity and its safety profile, 

- the selection pressure exerted by the fluoroquinolones,

- and the existence of treatment alternatives, including for the multidrug-resistant strains.